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Novelty and impact  
Findings on the relation between vitamin D and pancreatic cancer risk are conflicting. In our study, the 
largest combination of European studies to date, higher vitamin D concentrations are not associated with 
a lower risk of pancreatic cancer. Since findings across the globe are not consistent and the underlying 
mechanisms with respect to pancreatic cancer are unclear, caution is warranted before guidelines to 
increase vitamin D concentrations for the prevention of cancer can be recommended. 
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ABSTRACT 
Evidence from in vivo, in vitro and ecological studies are suggestive of a protective effect of vitamin D 
against pancreatic cancer. However, this has not been confirmed by analytical epidemiological studies. 
We aimed to examine the association between pre-diagnostic circulating vitamin D concentrations and 
pancreatic cancer incidence in European populations.  
We conducted a pooled nested case-control study within the European Prospective Investigation into 
Cancer and Nutrition (EPIC) and the Nord-Trøndelag Health Study’s second survey (HUNT2) cohorts. In 
total, 738 primary incident pancreatic cancer cases (EPIC n=626; HUNT2 n=112; median follow-up = 6.9 
years) were matched to 738 controls. Vitamin D [25(OH)D2 and 25(OH)D3 combined] concentrations were 
determined using isotope-dilution liquid chromatography-tandem mass spectrometry. Conditional logistic 
regression models with adjustments for body mass index and smoking habits were used to estimate 
incidence rate ratios (IRRs) and 95% confidence intervals (95%CI). 
Compared with a reference category of >50 to 75 nmol/L vitamin D, the IRRs (95% CIs) were 0.71 (0.42-
1.20); 0.94 (0.72-1.22); 1.12 (0.82-1.53); and 1.26 (0.79-2.01) for clinically pre-defined categories of ≤25; 
>25 to 50; >75 to 100; and >100 nmol/L vitamin D, respectively (p for trend = 0.09). Corresponding 
analyses by quintiles of season-standardized vitamin D concentrations also did not reveal associations 
with pancreatic cancer risk (p for trend = 0.23). 
Although these findings among participants from the largest combination of European cohort studies to 
date show increasing effect estimates of pancreatic cancer risk with increasing pre-diagnostic 
concentrations of vitamin D, they are not statistically significant. 
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INTRODUCTION 
Pancreatic cancer (PC) is a relatively rare form of cancer in Europe, with annual incidence rates of 
8.3/100,000 in men and 5.5/100,000 in women 1. However, it is an aggressive and devastating 
malignancy, which is characterised by invasiveness, rapid progression and resistance to treatment. As a 
result, 5-year survival rates in Europe are only 7% 2. Prevention is therefore key, but with the exception of 
family history, chronic pancreatitis, diabetes mellitus, smoking, alcohol and obesity as established risk 
factors 3, 4, a large part of the etiology of PC remains unknown. The identification of (other) modifiable risk 
factors is therefore warranted. 
A potentially interesting factor in this respect is vitamin D. In general, vitamin D and its derivatives have 
been shown to have significant anti-carcinogenic properties 5, 6. The expression of the enzyme 25-
hydroxyvitamin D-1 α –hydroxylase that catalyses the established biomarker of vitamin D status, 25(OH)D 
7, to the active vitamin D form, 1α,25(OH)2D, has been observed in pancreatic duct cells, and in normal 
and adenocarcinomatous tissues 8, 9. Furthermore, vitamin D analogs inhibit PC cell proliferation, induce 
differentiation, promote apoptosis and repress metastasis in vitro 10-18, and inhibit pancreatic tumour 
growth in vivo 12, 13, 16, 18. 
Ecological studies have shown that lower latitude and increased ultraviolet B (UVB) radiation are inversely 
related to PC risk and mortality 19-21 and a preventive role of vitamin D has been suggested. However, an 
ecological study design has several weaknesses and the validity of associations might be questioned. 
Analytical epidemiologic studies on vitamin D in relation to PC risk have been conducted, with conflicting 
results.  
In prospective nested case-control studies, blood concentrations of vitamin D have been investigated, 
which better reflects total vitamin D status. In the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer 
Prevention Study of male smokers from Finland 22, higher vitamin D concentrations were associated with 
an increased risk of PC, whereas no overall association was observed in a first report, but an increased 
risk was shown in a second report of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer 
Screening Trial from the United States (US)23, 24. When the ATBC and PLCO studies were combined with 
four other studies from the US and two from China in the Cohort Consortium Vitamin D Pooling Project of 
Rarer Cancers (VDPP), including 952 PC cases and 1333 controls, an increased risk with higher vitamin 
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D concentrations was observed 25. However, a pooled analysis of 451 PC cases and 1167 controls from 
five US studies, different from those in the VDPP, showed an inverse association 26. 
Except for the single study from Finland 22, which was based on male smokers only, no studies on vitamin 
D concentrations in relation to PC risk have been performed in European populations. Given the paucity of 
information from European populations, particularly from prospective cohort studies where biological 
samples are collected prior to cancer onset, we conducted a pooled nested case-control study within the 
European Prospective Investigation into Cancer and Nutrition (EPIC) and the Nord-Trøndelag Health 
Study’s second survey (HUNT2) cohorts to examine the association between pre-diagnostic circulating 
concentrations of vitamin D and the incidence of PC. 
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METHODS 
Study population 
Both the EPIC and HUNT2 cohorts have previously been described in detail 27, 28. In brief, EPIC is a multi-
centre prospective cohort study designed to investigate the association between diet, various lifestyle and 
environmental factors and the incidence of different forms of cancer and other chronic diseases. It 
consists of cohorts in 23 centres from 10 European countries: Denmark, France, Germany, Greece, Italy, 
the Netherlands, Norway, Spain, Sweden, and the United Kingdom. A total of 521,448 subjects joined the 
study between 1992 and 2000. Habitual dietary intake for the past 12 months was assessed using 
validated country-specific food frequency questionnaires 29, 30 and country-specific food composition 
tables.  Participants also completed a lifestyle questionnaire, had their anthropometric measurements 
recorded (self-reported in France, Norway and Oxford), and donated a blood sample (in approximately 
80% of cohort participants). These blood samples were processed, aliquoted and stored in heat-sealed 
straws at – 196 °C under liquid nitrogen at the International Agency for Research on Cancer (IARC) for all 
countries except Denmark and Sweden, where tubes were stored at -150 °C under nitrogen vapour or at -
80°C in freezers, respectively. 
Incident PC cases were identified through record linkage with regional cancer registries in Denmark, 
Norway, the Netherlands, Spain, Sweden, the United Kingdom, and in most of the Italian centres. In 
France, Germany, Greece, and Naples (Italy), follow-up  was based on a combination of methods, 
including health insurance records, cancer and pathology registries, and active follow-up through study 
participants and their next-of-kin. Closure dates for the present study were defined as the latest date of 
complete follow-up and ranged from December 2007 to December 2008 for centres using registry data, 
and from June 2005 to December 2009 for centres using active follow-up procedures. 
All participants gave written informed consent, and the study was approved by the Ethics Review 
Committee of IARC and by the local ethical committee of individual EPIC centres.  
The HUNT study was initiated in 1984, inviting the total adult population of over 20 years of age in the 
county of Nord-Trøndelag in Norway for a general population-based health screening. The main emphasis 
was initially on hypertension and diabetes, but this was later extended to include a large number of health 
problems and disease categories. For the current analyses, the 65,237 participants of the second HUNT 
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survey (HUNT2) were included. Between 1995-1997 these participants filled out questionnaires on a wide 
range of topics (e.g. use of alcohol and tobacco, physical activity and medical history), had a clinical 
examination and donated a blood sample. These samples were stored in a biobank at -80 0C. 
Based on the unique national identity number, assigned to all Norwegian residents, the participants in 
HUNT are linked to different national registries to access migration, emigration, cancer incidence and 
mortality data. The last record linkages for the present study with the Norwegian Cancer Registry 
identified cancer cases diagnosed until September 2007. 
All participants gave written informed consent at baseline, including future linkage to national registries, 
and the study was recommended by the Regional Committee for Medical Research Ethics and approved 
by the Data Inspectorate of Norway. 
 
Nested case-control design 
Cases in this study included primary incident pancreatic adenocarcinomas (International Classification of 
Diseases for Oncology, Third Edition, codes C250–C259 or C25.0–C25.3 and C25.7–C25.9). Endocrine 
pancreatic tumours (code C25.4; histology types 8150, 8151, 8153, 8155, 8240 and 8246) were excluded, 
because the aetiology of these cancers may be different.  
During the follow-up period, 1013 PC cases were identified in the EPIC cohort. Of these, 33 endocrine 
cases were excluded. After further exclusions [283 cases who did not have blood sample available, 2 
cases who had in situ tumours or tumours of non-malignant morphology, 65 cases who had a secondary 
tumour, and 4 cases who did not have lifestyle data available], a total of 626 incident PC cases with 
available questionnaire data and blood samples were identified for the present study. 
In the HUNT2 cohort, 117 PC cases were identified, of which 5 endocrine tumours were excluded, leaving 
112 incident cases for the present study.   
Among this total of 738 cases, 493 (67%) were microscopically confirmed, based on histology of the 
primary tumour (N=251), histology of the metastasis (N=82), cytology (N=117) or autopsy (N=43). 
 
Control subjects were selected by incidence density sampling from all cohort members alive and free of 
cancer (except non-melanoma skin cancer) at the time of diagnosis of the matching case and were 
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matched to cases by study centre, sex, duration of follow-up, age at blood collection (+/- 1 month to +/- 5 
years), and fasting status at the time of blood collection (< 3 hours (not fasting), 3-6 hours (in between) or 
> 6 hours (fasting)). For the EPIC study, participants were also matched on date of blood collection (+/- 1 
month to +/- 1 year) and time of blood collection (+/- 1 hour to +/- 4 hours). For every case one matched 
control was identified. 
 
Laboratory measurements 
Concentrations of both forms of vitamin D status [25(OH)D2 and 25(OH)D3] were measured in blood 
serum [plasma for the samples of Umea (Sweden)], using isotope-dilution liquid chromatography (LC) 
tandem-mass spectrometry (MS/MS) 31, at the department of clinical chemistry, Canisius Wilhelmina 
Hospital in Nijmegen, the Netherlands. The inter-assay coefficients of variation (CV) were 5.3%, 3.1% and 
2.9% at 25(OH)D3 concentrations of 39.0, 92.5 and 127.0, nmol/L, respectively, and 9.5%, 5.5% and 5.6% 
at 25(OH)D2 concentrations of 32.9, 57.3 and 111.0 nmol/L, respectively. For technical reasons, EPIC and 
HUNT2 samples were measured sequentially. In addition, 11% of case-control sets were not measured in 
the same analytical batch. However, batch to batch differences are considered to be minor: no significant 
between-day drift, time shifts or other trends were observed. For all analyses, laboratory technicians were 
blinded to case-control status of the samples. 
Concentrations of 25(OH)D2 were only observed in 24 persons (1.6%) of the population, of which 3 came 
from Denmark, 4 from Spain, 13 from Sweden and 4 from the HUNT2 cohort in Norway. For the current 
analyses, total vitamin D status was evaluated by adding 25(OH)D2 to 25(OH)D3 concentrations. 
 
Data analysis 
Means with standard deviations, medians with interquartile ranges or frequencies (where appropriate) of 
baseline characteristics were computed and compared between cases and controls of the EPIC and 
HUNT2 cohorts separately. Differences between cases and controls were tested by paired t-test or by 
conditional logistic regression. 
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An incidence rate ratio (IRR), which is the interpretation of an odds ratio in an incidence density sampling 
design 32, and 95% confidence interval (95% CI) for the association between vitamin D status and PC was 
estimated by conditional logistic regression analysis.  
To compare our findings with results from literature, vitamin D concentrations were divided into 5 
categories (≤25; >25 to 50; >50 to 75; >75 to 100; and >100 nmol/L) according to clinically defined cut-
points, which are based on the proposed levels of vitamin D deficiency, insufficiency and sufficiency 33-36. 
The middle category was used as reference in order to provide stability in the statistical analyses.  To test 
for trend across categories, the categories of vitamin D were modelled as continuous variables, in which 
each category was assigned the median value of controls in that category. 
In addition, vitamin D concentrations were divided into overall quintiles as well as cohort-specific quintiles, 
defined by the distribution in control subjects. Vitamin D concentrations were also log2-transformed. The 
IRR for a log2-transformed variable corresponds to the change in PC risk by doubling the blood 
concentrations. 
Since season of blood collection may affect vitamin D levels, two approaches were used to take this into 
account: a) adjustment for month of blood collection; b) standardization of vitamin D levels by adding the 
overall mean of vitamin D for all subjects to the residuals derived from 1) a simple regression model fitted 
to vitamin D concentration by month of blood collection, 2) a regression of vitamin D levels on the periodic 
function – sin(2πX/12) – cos (2πX/12), where X is the month of blood collection; and 3) a non-parametric 
local regression (PROC LOESS; SAS Institute, Cary, NC) with vitamin D status as the dependent variable 
and week of the year of blood donation as the independent variable 37, 38. Since the results were similar for 
all different approaches to take seasonal variation into account, adjustment by LOESS residuals was used 
in all final models on quintiles and a doubling of vitamin D concentrations. 
IRR estimates were computed both in a crude model, which was conditioned on the matching factors, and 
in a multivariable model, which was developed by individually adding variables to the model. Variables 
examined as potential confounders were body mass index (BMI; weight (kg)/height(m)2), waist-to-hip ratio, 
waist circumference (cm), hip circumference (cm), alcohol consumption (g/d), physical activity (inactive, 
active), smoking habits (never smokers, former smokers who quitted ≥ 15 years earlier, former smokers 
who quitted between 0-15 years earlier, currents smokers who smoke < 15 cigarettes/day, current 
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smokers who smoke ≥ 15 cigarettes/day, former/current smokers with years since quitting/dose unknown), 
smoking duration, educational level (primary school or less, secondary school lower level, secondary 
school higher level, college/university degree), diabetes (yes, no), any vitamin use (yes, no), and season 
of blood collection (winter: December-February; spring: March-May; summer: June-August; autumn: 
September-November). The final multivariable model included BMI and smoking habits as these were 
associated with both the disease and the risk factor and changed the risk estimate by 10% or more. The 
dietary variables red meat, processed meat, and fruit and vegetable intake were also investigated as 
potential confounders for cases and controls from the EPIC study, but they did not change the point 
estimates appreciably and were therefore not included in any model.  
To evaluate whether preclinical disease may have influenced the results, additional analyses were 
conducted after exclusion of cases that were diagnosed within two year after recruitment and their 
matched controls (leaving approximately 87% of the population). In addition, the association between 
vitamin D and pancreatic cancer was examined by tertiles of follow-up time. Further sensitivity analyses 
were performed in which only microscopically confirmed PC cases (67%) and their matched controls were 
included. 
Possible heterogeneity of effects by log2 transformed values of vitamin D levels between categories of 
matching factors [age groups (median split), sex, season of blood collection, region (North: Norway, 
Sweden, Denmark, the Netherlands, Germany, and United Kingdom; South: France, Italy, Spain, and 
Greece), latitude (30-50 and 50-70 ⁰N) and country] was tested using the heterogeneity statistic derived 
from the inverse variance method.  
Joint effects of several factors (in median split or pre-defined categories) with season-standardized vitamin 
D concentrations (in quartiles) were calculated, for which a combined reference category of the lowest 
category of these factors with a low vitamin D concentration was used. These factors are BMI, physical 
activity, smoking status, alcohol consumption, multivitamin use, diabetes at baseline, calcium intake (only 
available for the EPIC cohort), and retinol intake (only available for the EPIC cohort). Interaction (on the 
multiplicative scale) was tested by including a product term of the above-mentioned factors with season-
standardized vitamin D status into the model. In addition, heterogeneity of effects by log2 transformed 
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values of vitamin D levels by strata of the above-mentioned factors were tested using the heterogeneity 
statistic derived from the inverse variance method.  
All analyses were performed using SAS Software (version 9.3, SAS Institute Inc, Cary, NC, USA). For all 
analyses two-sided p-values < 0.05 were considered statistically significant. 
 
RESULTS  
In the EPIC cohort, the mean age of PC cases was 57.7 years at recruitment and they were followed for 
7.0 years on average (Table 1). PC cases from EPIC were heavier, had a larger waist circumference and 
waist-hip ratio, were more likely to be current smokers and to have diabetes than controls.  
In the HUNT2 cohort, the mean age of PC cases was 68.0 years at recruitment and they were followed for 
5.8 years on average. PC cases from HUNT2 were more likely to be current smokers and tended to have 
a longer duration of smoking than controls. 
When pre-defined cut-points of vitamin D concentrations were investigated in relation to PC risk, a trend 
was observed, which was not statistically significant (p for trend = 0.09; Table 2). Compared with the 
reference (> 50 to 75 nmol/L), lower vitamin D levels showed decreased effect estimates (≤ 25.0 nmol/L: 
IRR (95% CI)=0.71 (0.42-1.20); >25 to 50 nmol/L: 0.94 (0.72-1.22)), whereas higher levels showed 
increased effect estimates (>75 to 100 nmol/L = 1.12 (0.82-1.53); >100 nmol/L = 1.26 (0.79-2.01)) in the 
adjusted model. 
Season-standardized circulating vitamin D concentrations were not associated with risk of PC (Table 2). 
Compared with the lowest overall quintile (Q1), IRRs with 95% CIs were 1.32 (0.95-1.85) for Q2, 1.14 
(0.81-1.62) for Q3, 1.18 (0.83-1.69) for Q4 and 1.38 (0.94-2.01) for Q5 (p for trend = 0.23). Effect 
estimates for cohort-specific quintiles were comparable. A doubling of vitamin D concentrations was also 
not associated with PC risk (IRR (95% CI) = 1.16 (0.95-1.41). A model that, in addition to BMI and 
smoking habits, was further adjusted for waist-hip-ratio, physical activity, alcohol, diabetes, education, and 
vitamin use showed similar effect estimates (e.g. IRRlog2 (95% CI) = 1.20 (0.94-1.54)). 
When the first two years of follow-up were excluded (leaving approximately 87% of the population in the 
analyses), the trend over pre-defined cut-points reached statistical significance (p for trend 0.04), whereas 
the trend over season-standardized quintiles of vitamin D concentrations did not (p for trend 0.08). When 
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follow-up time was divided in tertiles, the trend over pre-defined cut-points as well as the one over season-
standardized quintiles was only statistically significant in the second tertile (p for trend for increasing 
tertiles of follow-up time = 0.48, 0.004 and 0.43 for pre-defined cut-points and 0.79, 0.004 and 0.51 for 
quintiles). 
The trends over pre-defined cut-points and season-standardized quintiles were not statistically significant 
when only confirmed PC cases (67%) were included in the analyses (p for trend 0.22 and 0.72, 
respectively).  
No heterogeneity was observed by age (IRRlog2 (95% CI) = 1.06 (0.79-1.42) for younger age and 1.29 
(0.97-1.72) for older age; pheterogeneity=0.34), sex (IRRlog2 (95% CI) = 1.13 (0.83-1.55) for men and 1.18 
(0.90-1.53) for women; pheterogeneity=0.86), season of blood collection (IRRlog2 (95% CI) = 0.87 (0.48-1.55) 
for winter, 0.90 (0.51-1.59) for spring, 0.94 (0.51-1.74) for summer and 1.16 (0.78-1.73) for autumn; 
pheterogeneity=0.82), region (IRRlog2 (95% CI) = 1.18 (0.94-1.48) for north and 1.14 (0.73-1.76) for south 
pheterogeneity=0.88), nor latitude (IRRlog2 (95% CI) = 1.07 (0.71-1.61) for 30-50⁰N and 1.20 (0.95-1.51) for 50-
70⁰N; pheterogeneity=0.63).  
Although none of the countries within the EPIC cohort separately showed a statistically significantly 
increased PC risk for every doubling of season-standardized vitamin D concentrations, all countries 
except Germany and Greece showed effect estimates above the null value (p for heterogeneity between 
EPIC countries = 0.97; Figure 1). The IRR (95% CI) for every doubling in season-standardized vitamin D 
concentrations was 1.08 (0.87-1.35) for the EPIC cohort, whereas it was 1.73 (1.00-3.01) for the HUNT2 
cohort (p for heterogeneity between EPIC and HUNT2 = 0.12; Figure 1).  
No interaction nor heterogeneity of effects was observed for vitamin D and any of the factors tested (Table 
3).  
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DISCUSSION  
In this study, the largest combination of European studies to date on this topic, higher vitamin D 
concentrations are not inversely associated with PC risk. In fact, increasing effect estimates of PC risk 
with a borderline statistically significant trend were observed with increasing pre-defined cut-points of 
vitamin D status, whereas season-standardized quintiles did not show an association with risk of PC.  
Our findings are fairly consistent with observations from other studies as hardly any of them showed 
evidence of an inverse association. Although optimal levels of 25(OH)D have not been definitively 
determined, a classification of clinically relevant cut-points has been used before. The VDPP 25 first used 
these cut-points, where a low vitamin D concentration (< 50 nmol/L) compared with a reference category 
of 50 - <75 nmol was not associated with PC risk, while a high vitamin D concentration (≥ 100 nmol/L)  
was associated with a statistically significant 2-fold increase in PC risk [OR (95% CI) = 2.12 (1.23-3.64) 25. 
The pooling project included participants from eight cohorts, among which were the ATBC study 22 and the 
PLCO cohort 23. Both these studies already published results on vitamin D status and PC risk, but divided 
vitamin D in quintiles instead of clinically defined cut-points. Using these quintiles, the ATBC study 
revealed a nearly 3-fold increase in PC risk for the highest quintile in comparison with the lowest quintile 
(OR (95% CI) = 2.92 (1.56-5.48; p for trend 0.001) 22. In the PLCO no association was observed in the 
overall analysis, but a nearly 4-fold increase in PC risk for the highest versus the lowest quintile ((OR 
(95% CI) = 3.91 (1.19-12.85; p for trend 0.10)) was shown in a subgroup of participants living at northern 
latitudes 23. In a subsequent analysis, using clinically defined cut-points, an increase in PC risk was 
observed for a high vitamin D concentration (≥ 100 nmol/L)  compared with a reference category of 50 - 
<75 nmol ((OR (95% CI) = 3.23 (1.24-8.44)) in the overall group of the PLCO study 24. The only study that 
did observe an inverse association between vitamin D concentrations and PC risk is a pooled analysis of 
participants from five cohorts 26. Here, the odds ratio for the highest quintile of vitamin D concentrations 
compared with the lowest quintile was 0.67 (95% CI 0.46-0.97; p for trend 0.03). The inverse linear 
association observed for quintiles was not observed when Wolpin et al. divided vitamin D concentrations 
according to clinically relevant cut-points as defined in the VDPP study 26. However, they also did not 
observe an increased PC risk for high vitamin D concentrations of ≥100 nmol/L. Although we did not 
detect a direct association between high vitamin D concentrations and PC either, effect estimates seemed 
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to increase with increasing concentrations of vitamin D. In light of these results, we cannot state that 
higher vitamin D concentrations are related to a higher PC risk, but it seems reasonable to conclude that 
higher vitamin D concentrations are not related to a lower PC risk in this population. 
Except for the ATBC study from Finland 22, this is the first study on vitamin D concentrations in relation to 
PC risk among European populations. One may hypothesize that this relation may differ with the 
associations observed in populations from the US, due to differences in latitude and fortified foods. Most 
of Europe lies above 37⁰N latitude, whereas this is only true for the northern half of the US. Since UVB is 
efficiently absorbed by the ozone layer from November through February above 37⁰N latitude39, 40, nearly 
all European residents have low, if any, endogenous vitamin D production during these months and are 
thus more dependent on vitamin D intake from foods and supplements than residents from the US. In 
addition, vitamin D fortification of foods differs between Europe and the US, where fortification of milk, for 
example is the exception in Europe rather than the rule in the US41. As the amount of vitamin D that was 
added to milk was not very consistent in the 1990s42, 43, it is less likely that hypothesized differences in 
associations between populations from the US and Europe are due to differences in food fortification than 
to differences in latitude. Even though there may be a difference in the sources of vitamin D 
concentrations between populations from Europe and the US, the vitamin D concentrations from our 
European study are comparable to those from US studies in the 1990s, and no large differences were 
observed for the association between vitamin D concentrations and PC risk. 
Although several in vitro and in vivo studies have shown that vitamin D has anti-carcinogenic properties in 
general 5, 6, few studies have investigated this specifically with respect to PC. Whether vitamin D has anti-
carcinogenic effects on the pancreas is thus largely unclear. The molecular basis by which vitamin D may 
be involved in pancreatic carcinogenesis should be further investigated. We propose that certain genetic 
variants affecting vitamin D concentrations may modulate the association between vitamin D and PC risk. 
Within the vitamin D pathway, genetic variants in the vitamin D binding protein (DBP, corresponding gene 
GC) are most frequently investigated. It is possible that variants in the DBP gene may affect the vitamin D 
binding protein concentration in the circulation and therefore may influence the vitamin D bioavailability, 
the role of which is unknown in pancreatic carcinogenesis. In a recent study of 713 PC cases and 818 
controls from five cohorts within the VDPP, the association between vitamin D concentrations and PC risk 
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was not modified by single nucleotide polymorphisms in the DBP gene or 10 other genes in the vitamin D 
metabolic pathway 44. Nevertheless, it should be kept in mind that in various Genome-Wide Association 
Studies on vitamin D concentrations, genetic variants in GC are among the significant findings 45, 46. To 
unravel the molecular mechanisms by which vitamin D may influence pancreatic carcinogenesis, more 
studies should investigate vitamin D-gene interactions with genetic variants in the vitamin D metabolic 
pathway, but also including the vitamin D receptor (VDR) and its vitamin D-mediated transcriptionally 
regulated (VDRE containing) genes and their signalling pathways 47. 
An important strength of this study is the prospective design with pre-diagnostic measurements of vitamin 
D concentrations, which reduces the influence of reversed causation. In addition, pooling two large 
European studies resulted in a relatively large study population. This population originates from countries 
from the north to the south of Europe, spanning a wide range of sun exposure, many different lifestyle 
patterns, dietary habits and PC incidence. A difference in vitamin D status was also observed between the 
two European studies, where higher concentrations of vitamin D were observed in the HUNT cohort from 
the North of Norway than in the more centrally located EPIC study. Although this is contrary to what would 
be expected based on latitude, this may be due to differences in study population, blood sample handling 
procedures or to a higher use of cod liver oil supplements, which is a long dietary tradition in Norway 48. 
Finally, another strength of this study is that all samples were transported to the same laboratory for 
measurement using a single LC-MS/MS method, which shows close agreement to a reference 
measurement procedure for 25(OH)D3 and 25(OH)D2 analysis in human serum 31.   
A limitation of this study is that only a single baseline measurement of vitamin D was used. Vitamin D 
levels display seasonal variability and a single measurement of vitamin D may not reflect long-term 
vitamin D status. However, the concentration of 25(OH)D in samples collected up to 14 years apart was 
observed to be sufficiently reliable to be used in cohort studies 49. Furthermore, we standardized the 
vitamin D concentrations by week of blood collection to take season of blood draw into account. While we 
could not take some risk factors of PC risk, such as family history and chronic pancreatitis, into account 
due to a lack of information, we did test other established PC risk factors and included BMI and smoking 
habits into the model to adjust for potential confounding. Although residual confounding by smoking 
19 
 
cannot be ruled out, it is not likely, because the findings observed in never smokers were similar to the 
overall result. 
In conclusion, among participants from the largest combination of European studies to date, higher vitamin 
D concentrations are not associated with a lower risk of PC. More research is needed on the molecular 
mechanisms by which vitamin D may influence pancreatic carcinogenesis. Until there is a better biological 
understanding of this mechanism, caution is warranted before guidelines to increase vitamin D 
concentrations in healthy persons for the prevention of cancer can be recommended.  
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Table 1. Description of pancreatic cancer cases and matched controls for the EPIC and HUNT2 studies 
separately 
 EPIC HUNT2 
Matched variables 
Cases  
(n=626) 
Matched 
controls  
(n=626) 
P 
value b 
Cases  
(n=112) 
Matched 
controls  
(n=112) 
P 
value b 
Years of follow-up, mean (sd) 7.0 (3.7) --- --- 5.8 (3.2) --- --- 
Age at recruitment, years,  
mean (sd) 57.7 (7.8) 57.7 (7.8) --- 68.0 (10.7) 68.0 (10.6) --- 
Women, n (%) 337 (53.9) 337 (53.9) --- 59 (52.7) 59 (52.7) --- 
Residential region, n (%)   ---   --- 
North (UK, NL, Germany, Denmark, 
Sweden, Norway) 457 (73.0) 457 (73.0)  112 (100.0) 112 (100.0)  
South (France, Italy, Spain, Greece) 169 (27.0) 169 (27.0)  --- ---  
Country, n (%)       
HUNT2 cohort      --- 
Norway --- ---  112 (100.0) 112 (100.0)  
EPIC cohort   ---    
Denmark 79 (12.6) 79 (12.6)  --- ---  
France 12 (1.9) 12 (1.9)  --- ---  
Germany 86 (13.7) 86 (13.7)  --- ---  
Greece 36 (5.8) 36 (5.8)  --- ---  
Italy 66 (10.5) 66 (10.5)  --- ---  
The Netherlands 62 (9.9) 62 (9.9)  --- ---  
Norway 5 (0.8) 5 (0.8)  --- ---  
Spain 55 (8.8) 55 (8.8)  --- ---  
Sweden 145 (23.2) 145 (23.2)  --- ---  
United Kingdom 80 (12.8) 80 (12.8)  --- ---  
Season of blood collection, n (%)   ---   --- 
Winter (Dec, Jan, Feb) 134 (21.4) 135 (21.6)  24 (21.4) 25 (22.3)  
Spring (Mar, Apr, May) 190 (30.4) 197 (31.5)  26 (23.2) 25 (22.3)  
Summer (Jun, Jul, Aug) 125 (20.0) 123 (19.7)  19 (17.0) 19 (17.0)  
Autumn (Sep, Oct, Nov) 177 (28.3) 171 (27.3)  43 (38.4) 43 (38.4)  
Fasting status, n (%)   ---   --- 
< 3 hrs 253 (40.4) 263 (42.0)  78 (69.6) 80 (71.4)  
3-6 hrs 100 (16.0) 97 (15.5)  32 (28.6) 31 (27.7)  
> 6 hrs 171 (27.3) 165 (26.4)  1 (0.9) 1 (0.9)  
Use of pill/HRT/ERT at blood 
collection, yes, n (%) 56 (9.0) 56 (9.0) --- 6 (5.4) 6 (5.4) --- 
Characteristics       
Height, cm, mean (sd) 167.7 (9.4) 167.2 (9.7) 0.20 166.5 (9.6) 166.3 (8.9) 0.87 
Weight, kg, mean (sd) 74.7 (13.6) 73.4 (13.9) 0.06 75.1 (13.6) 74.3 (12.6) 0.55 
BMI, kg/m2, mean (sd) 26.6 (4.2) 26.2 (4.1) 0.13 27.0 (3.9) 26.8 (3.8) 0.61 
Waist circumference, cm, mean (sd) 89.8 (12.8) 88.3 (12.9) 0.02 90.4 (11.5) 89.3 (10.8) 0.38 
Hip circumference, cm, mean (sd) 101.8 (8.6) 101.1 (8.3) 0.2 103.5 (8.8) 102.6 (6.9) 0.33 
Waist-hip-ratio, mean (sd) 0.9 (0.1) 0.9 (0.1) 0.01 0.9 (0.08) 0.9 (0.09) 0.79 
Education level, n (%)   0.20   0.45 
Primary school or less 278 (44.4) 248 (39.6)  53 (47.3) 57 (50.9)  
Secondary school lower level 142 (22.7) 166 (26.5)  33 (29.5) 28 (25.0)  
Secondary school higher level 73 (11.7) 79 (12.6)  1 (0.9) 5 (4.5)  
College/University degree 113 (18.1) 116 (18.5)  6 (5.4) 13 (11.6)  
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Smoking status, n (%)   <0.01   0.08 
Never 233 (37.2) 287 (45.9)  40 (35.7) 48 (42.9)  
Past 183 (29.2) 201 (32.1)  36 (32.1) 43 (38.4)  
Current 201 (32.1) 133 (21.3)  26 (32.1) 21 (18.8)  
Age start smoking, years,  
mean (sd) 20.1 (6.5) 20.3 (6.4) 0.43 22.8 (8.5) 21.0 (8.1) 0.79 
Duration of smoking, years,  
mean (sd) 29.4 (12.0) 27.4 (12.9) 0.19 32.5 (14.7) 29.6 (14.8) 0.09 
Time since quitting, years,  
mean (sd) 16.0 (11.5) 16.0 (10.3) 0.16 18.1 (11.6) 21.8 (13.2) 0.74 
Smoking dose, cig/day, mean (sd) 15.7 (8.4) 16.3 (8.8) 0.35 10.9 (6.4) 10.2 (6.2) 0.16 
Smoking habits combined, n (%)   <0.01   0.15 
Never 233 (37.2) 287 (45.9)  40 (35.7) 48 (42.9)  
Former, time since quitting > 15 yrs 87 (13.9) 89 (14.2)  18 (16.1) 27 (24.1)  
Former, time since quitting 0 - 15 yrs 90 (14.4) 103 (16.5)  15 (13.4) 14 (12.5)  
Current, 0 - 15 cig/day 97 (15.5) 60 (9.6)  27 (24.1) 17 (15.2)  
Current, > 15 cig/day 80 (12.8) 52 (8.3)  7 (6.3) 1 (0.9)  
Former/current, quitting/dose unknown 30 (4.8) 30 (4.8)  5 (4.5) 5 (4.5)  
Physical activity, n (%)   0.53   0.59 
inactive 174 (27.8) 184 (29.4)  12 (10.7) 12 (10.7)  
active 432 (69.0) 426 (68.1)  73 (65.2) 80 (71.4)  
Diabetes, yes, n (%) 45 (7.2) 28 (4.5) 0.03 4 (3.6) 7 (6.3) 0.37 
Vitamin D status       
Serum 25(OH)D, nmol/L, mean (sd) 60.0 (27.3) 59.4 (27.1) 0.57 70.7 (23.8) 64.7 (20.3) 0.05 
Quintiles of serum 25(OH)D   0.35   0.18 
Q1, n (%) 118 (18.9) 139 (22.2)  9 (8.0) 9 (8.0)  
Q2, n (%) 144 (23.0) 126 (20.1)  13 (11.6) 21 (18.8)  
Q3, n (%) 131 (21.0) 121 (19.3)  26 (23.2) 26 (23.2)  
Q4, n (%) 105 (16.8) 118 (18.9)  23 (20.5) 31 (27.7)  
Q5, n (%) 128 (20.5) 122 (19.5)  41 (36.6) 25 (22.3)  
Predefined cut-points of serum 
25(OH)D   0.90   0.26 
≤25 nmol/l, n(%) 33 (5.3) 39 (6.2)  1 (0.9) 4 (3.6)  
>25 to 50 nmol/L, n (%) 214 (34.2) 216 (34.5)  20 (17.9) 21 (18.8)  
>50 to 75 nmol/L, n (%) 233 (37.2) 232 (37.1)  46 (41.1) 56 (50.0)  
>75 to 100 nmol/L, n (%) 92 (14.7) 90 (14.4)  33 (29.5) 25 (22.3)  
> 100 nmol/L, n (%) 54 (8.6) 49 (7.8)  12 (10.7) 6 (5.4)  
Dietary variables       
Alcohol (g/day) a 6.0 (0.9-19.3) 5.7 (1.1-17.9) 0.64 1.4 (0.0-4.3) 0.7 (0.0-2.9) 0.13 
Any vitamin use, n (%)   0.36   0.22 
Yes 211 (33.7) 222 (35.5)  12 (10.7) 11 (9.8)  
No 337 (53.8) 323 (51.6)  11 (9.8) 17 (15.2)  
a Median (p25-p75). 
b P-values for differences in means between cases and controls were determined by paired t-test, whereas 
differences in categorical variables were determined by conditional logistic regression. No P-values were determined 
for years of follow-up, age at recruitment, sex, residential region, country, season of blood collection, fasting status 
and use of pill/HRT/ERT at blood collection, because these variables were used for matching. 
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Table 2. Incidence rate ratios (IRR) of pancreatic cancer according to predefined cut-points and standardized circulating concentrations of 25-hydroxy 
vitamin D 
 
PRE-DEFINED CUT-POINTS P for trend 
Vitamin D (nmol/L) ≤ 25 >25 to 50 >50 to 75 >75 to 100 >100  
N cases/controls 34/43 234/237 279/288 125/115 66/55   
Crude IRR b 0.78 (0.47-1.29) 1.0 (0.77-1.28) Ref 1.15 (0.85-1.56) 1.36 (0.87-2.13) 0.11 
N cases/controls 34/43 231/233 275/281 123/115 64/55   
Adjusted IRR c 0.71 (0.42-1.20) 0.94 (0.72-1.22) Ref 1.12(0.82-1.53) 1.26 (0.79-2.01) 0.09 
   
OVERALL QUINTILES  Doubling of concentration 
 Q1 Q2 Q3 Q4 Q5 P for trend  
Vitamin D (nmol/L) a ≤ 39.5 39.6 – 51.7 51.8 – 63.5 63.6 – 77.9 >78.0   
N cases/controls 133/148 159/148 138/146 143/148 165/148  738/738 
Crude IRR b Ref 1.20 (0.87-1.65) 1.08 (0.77-1.50) 1.10 (0.78-1.55) 1.31 (0.91-1.89) 0.27 1.11 (0.92-1.34) 
N cases/controls 131/146 158/143 134/144 141/146 163/148  727/727 
Adjusted IRR c Ref 1.32 (0.95-1.85) 1.14 (0.81-1.62) 1.18 (0.83-1.69) 1.38 (0.94-2.01) 0.23 1.16 (0.95-1.41) 
        
COHORT-SPECIFIC QUINTILES  Doubling of concentration 
 Q1 Q2 Q3 Q4 Q5 P for trend  
Vitamin D (nmol/L) a        
EPIC 
HUNT 
≤ 39.1 
≤ 45.1 
39.1 – 49.8 
45.1 – 57.7 
49.8 – 63.3 
57.7 – 66.4 
63.3 – 77.2 
66.4 – 78.5 
>77.2 
>78.5 
  
N cases/controls 136/148 150/147 146/148 138/147 168/148  738/738 
EPIC 
HUNT 
119/125 
17/23 
127/125 
23/22 
132/125 
14/23 
122/125 
16/22 
126/126 
42/22 
 626/626 
112/112 
Crude IRR b Ref 1.12 (0.81-1.55) 1.09 (0.79-1.51) 1.04 (0.74-1.47) 1.31 (0.91-1.88) 0.29 1.11 (0.92-1.34) 
N cases/controls 134/146 149/143 142/145 136/145 166/148  727/727 
EPIC 
HUNT 
118/124 
16/22 
126/121 
23/22 
128/122 
14/23 
120/123 
16/22 
124/126 
42/22  
616/616 
111/111 
Adjusted IRR c Ref 1.23 (0.88-1.73) 1.20 (0.85-1.69) 1.12 (0.79-1.59) 1.40 (0.96-2.04) 0.20 1.16 (0.95-1.41) 
a Standardized by week of blood collection using LOESS residuals 
b Conditioned on matching factors [study centre, sex, duration of follow-up, age and fasting status at time of blood collection, use of oral contraceptives and/or 
hormone replacement therapy (only women) and date and time of blood collection (only EPIC)] 
c Conditioned on matching factors and adjusted for BMI and smoking habits 
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Table 3. Joint effectsa of potential effect modifiers with quartiles, and strata of potential effect modifiers by doubling of concentrations, of standardized 
circulating 25-hydroxy vitamin D in relation to PC risk 
Vitamin D status 
(nmol/L)    Q1 Q2 Q3 Q4 
P  
inter-
actionb 
Doubling of 
concentration 
P 
hetero-
geneityc 
BMI N (cases/ 
controls)  
163/183 194/179 173/182 197/183    
< 25.0 kg/m2 283/298 Ref 1.18 (0.70-2.00) 1.40 (0.83-2.36) 1.30 (0.78-2.20) 0.47 1.27 (0.75-2.18) 0.97 
≥ 25.0 kg/m2 444/429 0.95 (0.55-1.64) 1.32 (0.78-2.24) 0.97 (0.57-1.66) 1.31 (0.75-2.26)  1.26 (0.91-1.74)  
         
Physical activity   151/172 173/165 162/162 184/171    
Inactive 181/186 Ref 1.29 (0.73-2.26) 0.85 (0.46-1.57) 0.90 (0.47-1.72) 0.30 1.08 (0.52-2.24) 0.88 
Active 489/484 0.86 (0.52-1.41) 1.14 (0.70-1.85) 1.21 (0.75-1.97) 1.34 (0.81-2.21)  1.02 (0.77-1.35)  
         
Smoking status   163/183 194/179 173/182 197/183    
Never 272/330 Ref 1.29 (0.81-2.07) 1.13 (0.71-1.78) 1.55 (0.93-2.59) 0.52 0.94 (0.60-1.48) 0.96 
Former 218/243 0.94 (0.52-1.70) 1.38 (0.83-2.28) 1.59 (0.95-2.65) 1.58 (0.93-2.66)  1.13 (0.58-2.21)  
Current 237/154 2.66 (1.56-4.56) 3.46 (1.94-6.18) 2.18 (1.21-3.92) 2.45 (1.41-4.27)  0.90 (0.47-1.72)  
         
Alcohol   153/175 179/164 157/159 171/162    
< 5.0 g/day (median) 315/322 Ref 1.27 (0.81-1.98) 1.25 (0.78-1.99) 1.22 (0.76-1.97) 0.90 1.24 (0.83-1.85) 0.98 
≥ 5.0 g/day 345/338 0.98 (0.62-1.54) 1.41 (0.90-2.22) 1.18 (0.74-1.90) 1.43 (0.87-2.34)  1.23 (0.85-1.78)  
         
Multivitamin use   123/143 145/130 137/136 144/140    
No  338/327 Ref 1.40 (0.91-2.15) 1.24 (0.79-1.94) 1.50 (0.93-2.42) 0.80 1.12 (0.78-1.62) 0.60 
Yes 211/222 0.96 (0.52-1.75) 1.27 (0.77-2.11) 1.24 (0.75-2.05) 1.09 (0.65-1.81)  1.33 (0.75-2.36)  
         
Diabetes   160/180 190/173 167/175 186/175    
No 657/669 Ref 1.30 (0.95-1.78) 1.10 (0.79-1.53) 1.27 (0.89-1.81) 0.67 1.18 (0.95-1.45) --- 
Yes 46/34 0.94 (0.36-2.43) 1.60 (0.65-3.94) 2.23 (0.83-5.99) 2.20 (0.72-6.70)  Sample too small 
 
         
Calcium (only EPIC)   149/165 169/152 144/146 150/149    
< 959 mg/day (median) 303/313 Ref 1.50 (0.94-2.39) 1.25 (0.79-1.98) 1.43 (0.86-2.37) 0.73 1.15 (0.70-1.89) 0.85 
≥ 959 mg/day 309/299 1.36 (0.85-2.19) 1.56 (0.99-2.46) 1.45 (0.90-2.33) 1.34 (0.90-2.33)  1.08 (0.72-1.62)  
         
Retinol (only EPIC)   149/165 169/152 144/146 150/149    
< 700 ug/day (median) 296/315 Ref 1.26 (0.83-1.91) 1.31 (0.82-2.09) 1.32 (0.79-2.19) 0.68 1.44 (0.97-2.15) 0.10 
≥ 700 ug/day 316/297 1.23 (0.74-2.04) 1.67 (1.04-2.67) 1.22 (0.77-1.93) 1.27 (0.78-2.05)  0.96 (0.62-1.48)  
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a Conditioned on matching factors and adjusted for BMI and smoking habits. 
b Interaction (on the multiplicative scale) was tested by including a product-term of characteristics with quartiles of vitamin D in the model. 
c Possible heterogeneity of effects by log2 transformed values of vitamin D levels between strata of potential effect modifiers was tested using the heterogeneity 
statistic derived from the inverse variance method. 
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Figure 1. Country-specific incidence rate ratios (95% CI) of pancreatic cancer according to a doubling of standardized circulating 25-hydroxy vitamin D 
concentrations. 
Conditioned on matching factors and adjusted for BMI and smoking habits.  
No incidence rate ratios were obtained for EPIC-Norway due to the small population. 
P-value for heterogeneity between EPIC-countries was 0.97 and between the EPIC & HUNT2 cohorts was 0.12.   
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